Rocket Pharmaceuticals 향후 성장

Future 기준 점검 2/6

Rocket Pharmaceuticals (는) 각각 연간 12.7% 및 66% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 23.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -52.4% 로 예상됩니다.

핵심 정보

12.7%

이익 성장률

23.40%

EPS 성장률

Biotechs 이익 성장	23.8%
매출 성장률	66.0%
향후 자기자본이익률	-52.40%
애널리스트 커버리지	Good
마지막 업데이트	18 Nov 2025

최근 향후 성장 업데이트

Recent updates

Rocket Pharmaceuticals: Deep Dislocation Offers Asymmetric Upside On LAD-I Approval And Amended Danon Program

Dec 26

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Jun 09

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Apr 05

Rocket Pharmaceuticals' Promising Path In Gene Therapy

Mar 01

Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Nov 07

Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering

Oct 03

Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate

Aug 25

We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Jul 22

Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs

Jul 08

Rocket Pharma: Poised For Growth In The Rare Disease Space

Jun 30

Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside

Jan 30

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Nov 09

Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes

Oct 01

이익 및 매출 성장 예측

NasdaqGM:RCKT - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	21	-198	-159	-125	9
12/31/2026	17	-197	-125	-140	12
12/31/2025	N/A	-230	-215	-186	12
9/30/2025	N/A	-241	-203	-202	N/A
6/30/2025	N/A	-257	-206	-204	N/A
3/31/2025	N/A	-258	-213	-209	N/A
12/31/2024	N/A	-259	-216	-210	N/A
9/30/2024	N/A	-258	-202	-192	N/A
6/30/2024	N/A	-253	-210	-197	N/A
3/31/2024	N/A	-249	-210	-194	N/A
12/31/2023	N/A	-246	-211	-195	N/A
9/30/2023	N/A	-253	-236	-222	N/A
6/30/2023	N/A	-249	-219	-208	N/A
3/31/2023	N/A	-237	-206	-196	N/A
12/31/2022	N/A	-222	-186	-178	N/A
9/30/2022	N/A	-199	-160	-153	N/A
6/30/2022	N/A	-192	-147	-137	N/A
3/31/2022	N/A	-172	-145	-136	N/A
12/31/2021	N/A	-169	-129	-121	N/A
9/30/2021	N/A	-186	-122	-103	N/A
6/30/2021	N/A	-165	-108	-93	N/A
3/31/2021	N/A	-155	-92	-77	N/A
12/31/2020	N/A	-140	-95	-75	N/A
9/30/2020	N/A	-99	-98	-81	N/A
6/30/2020	N/A	-89	-98	-75	N/A
3/31/2020	N/A	-82	-99	-71	N/A
12/31/2019	N/A	-77	-88	-65	N/A
9/30/2019	N/A	-85	-81	-66	N/A
6/30/2019	N/A	-82	N/A	-67	N/A
3/31/2019	N/A	-79	N/A	-58	N/A
12/31/2018	N/A	-75	N/A	-54	N/A
9/30/2018	N/A	-54	N/A	-39	N/A
6/30/2018	N/A	-44	N/A	-31	N/A
3/31/2018	N/A	-32	N/A	-24	N/A
12/31/2017	N/A	-20	N/A	-16	N/A
9/30/2017	N/A	-16	N/A	-12	N/A
6/30/2017	N/A	-11	N/A	-9	N/A
3/31/2017	N/A	-9	N/A	-8	N/A
12/31/2016	N/A	-8	N/A	-6	N/A

애널리스트 향후 성장 전망

수입 대 저축률: RCKT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: RCKT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: RCKT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: RCKT 의 수익(연간 66%)이 US 시장(연간 10.7%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: RCKT 의 수익(연간 66%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: RCKT는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/28 14:52
종가	2025/12/26 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Rocket Pharmaceuticals, Inc.는 23명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Jason Zemansky	BofA Global Research
Whitney Ijem	Canaccord Genuity
Joshua Schimmer	Cantor Fitzgerald & Co.

Rocket Pharmaceuticals 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Consensus revenue estimates fall by 11%

Consensus revenue estimates decrease by 57%, EPS upgraded

No longer forecast to breakeven

Forecast to breakeven in 2026

Consensus revenue estimates fall by 95%

Price target decreased to US$53.18

Recent updates

Rocket Pharmaceuticals: Deep Dislocation Offers Asymmetric Upside On LAD-I Approval And Amended Danon Program

We're Keeping An Eye On Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Rocket Pharmaceuticals, Inc. Announces FDA Acceptance of BLA Resubmission of KRESLADI for Treatment of Severe Leukocyte Adhesion Deficiency-I

Rocket Pharmaceuticals, Inc. Announces Resignation of Pedro Granadillo from Board of Directors, Effective September 30, 2025

Rocket Pharmaceuticals, Inc. Announces CFO Changes

Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?

Rocket Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

Rocket Pharmaceuticals, Inc. Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

Rocket Pharmaceuticals, Inc. Announces Executive Changes, Effective July 7, 2025

Rocket Pharmaceuticals, Inc. Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

Rocket Pharmaceuticals, Inc. Provides Update on Phase 2 Clinical Trial of Rp-A501 for Danon Disease

Rocket Pharmaceuticals, Inc. Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2025

Rocket Pharmaceuticals, Inc Appoints Sarbani Chaudhuri as Chief Commercial & Medical Affairs Officer, Effective from April 7, 2025

We're Keeping An Eye On Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Rocket Pharma Is A Buy At These Prices With Promising Data

Rocket Pharmaceuticals, Inc. Announces Board Changes

Rocket Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $165 million.

Rocket Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Rocket Pharmaceuticals: Not Bad Valuation But Reflexivity Risks Remain

Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?

Rocket Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review

Rocket Pharmaceuticals, Inc. Appoints Mikael Dolsten to the Board

Rocket Pharmaceuticals, Inc. Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)

Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

CEO & Director recently sold US$229k worth of stock

CEO & Director notifies of intention to sell stock

Consensus revenue estimates fall by 11%

Rocket Pharmaceuticals Presents Positive Data from Lv Hematology Portfolio At the 27Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

New minor risk - Profitability

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Independent Director notifies of intention to sell stock

Insider recently sold US$309k worth of stock

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Rocket Pharmaceuticals, Inc. Announces Executive Appointments

Consensus revenue estimates decrease by 57%, EPS upgraded

VP, Senior Controller notifies of intention to sell stock

Rocket Pharmaceuticals' Promising Path In Gene Therapy

No longer forecast to breakeven

New minor risk - Insider selling

CEO & Director recently sold US$605k worth of stock

CEO & Director notifies of intention to sell stock

Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi™ (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

New minor risk - Profitability

Forecast to breakeven in 2026

Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director

New major risk - Revenue and earnings growth

New minor risk - Profitability

Rocket Pharmaceuticals, Inc. Announces Fda Acceptance of Biologics License Application with Priority Review for Rp-L201 (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

Rocket Pharmaceuticals Receives European Medicines Agency (Ema) Priority Medicines (Prime) Designation for RP-A501 Gene Therapy for Danon Disease

CEO & Director recently sold US$88k worth of stock

Rocket Pharmaceuticals, Inc. Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Insufficient new directors

Insider notifies of intention to sell stock

Consensus revenue estimates fall by 95%

CEO & Director notifies of intention to sell stock

Insider recently sold US$68k worth of stock

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease

Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM

Now 23% undervalued

Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering

Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate

Price target decreased to US$53.18

We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs